Nocuous Skin Manifestations of Spironolactone: Drug Induced Leukocytoclastic Vasculitis
Journal Title: Archives of Diabetes & Obesity - Year 2018, Vol 1, Issue 1
Abstract
The author discusses a case of drug induced vasculitis caused by spironolactone which is very rare complication of the drug. The authors give account on the type of vasculitis caused by drug induced allergy and also the differential diagnoses if the presentation is unusual with only hematuria and kidney injury. The benefits of Spironolactone and the side effects are also illustrated. 83 year-old Caucasian female with past medical history of hypertension, chronic kidney disease stage3-4 secondary to hypertensive nephrosclerosis with minimal proteinuria, hypokalemia, and Sjugrene syndrome without extra-glandular involvement. The patient was admitted to hospital because of urinary tract infection and edema of the lower extremities. She was treated with antibiotics, and diuretics for the edema. Her blood pressure was not optimum at this visit and spironolactone 25mg was added to her medication to control her BP, hypokalemia, and proteinuria. She was on amlodipine, frusemide, clonidine, Irbesartan, and potassium supplement. The treating nephrologist decided to try spironolactone for better control of high BP and hypokalemia and phased out the potassium supplementation. At this encounter her micro-albumin-creatinine ratio was 379.3mg/ gr, (normal value <29.9mg/gr creatinine). Physical examination was otherwise normal except bilateral leg edema, and high blood pressure (149/65mmHg). Her estimated glomerular filtration rate (EGFR) was 28ml/min).
Authors and Affiliations
Awad Magbri, Saad Rashid, Zach Crowe, Shaukat Rashid
Keywords
Related Articles
- EP ID EP583336
- DOI 10.32474/ADO.2018.01.000103
- Views 58
- Downloads 0
Diet, Obesity and Diabetes
Obesity and diabetes have become a very important global problem. In developed countries the incidence of both seems to have stabilised probably due to greater awareness and better education. Weight reduction in obese su...
Differences in participant classification and intervention effects based on HbA1C and fasting plasma glucose among a community sample of African Americans
Since 2010, the American Diabetes Association has endorsed both HbA1C (A1C) and fasting plasma glucose (FPG) to determine diabetes risk. Given the discordance between classifications based on FPG and A1C and higher A1C l...
Integration of Novel Emerging Technologies for the Management of Type-2 Diabetes
The incidence of twin epidemics, obesity and type-2 diabetes are increasing rapidly worldwide in the past two decades [1-7]. By azand large, clinicians manage diabetes by meticulous management of blood glucose levels to...
Excess Weight, Obesity, Diabetes (Type-2), and Clinical Complications
According to the National Institutes of Diabetes, Digestive and Kidney Diseases of the National Institute of Health, USA, approximately two-thirds of all adults in the USA (167 million), are overweight and a third is obe...
Management of Hypoglycemia in Patients with Type 2 Diabetes
The rate limiting step of intensive diabetes management for patients with diabetes is treatment induced hypoglycemia. Thus, hypoglycemia remains a significant barrier in optimizing glycemic control and reducing long-term...